Artelo Biosciences Stock Revenue
| ARTL Stock | USD 0.95 0.01 1.04% |
Artelo Biosciences fundamentals help investors to digest information that contributes to Artelo Biosciences' financial success or failures. It also enables traders to predict the movement of Artelo Stock. The fundamental analysis module provides a way to measure Artelo Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artelo Biosciences stock.
| Last Reported | Projected for Next Year |
Artelo | Revenue |
Artelo Biosciences Company Revenue Analysis
Artelo Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Artelo
Projected quarterly revenue analysis of Artelo Biosciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Artelo Biosciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Artelo Biosciences' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Artelo Biosciences reported 0.0 of revenue. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Artelo Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in revenue category among its peers.
Artelo Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Artelo Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Artelo Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Artelo Biosciences' value.| Shares | Geode Capital Management, Llc | 2024-12-31 | 17.4 K | Ubs Group Ag | 2024-12-31 | 13.3 K | Tower Research Capital Llc | 2024-12-31 | 3.8 K | Bank Of America Corp | 2024-12-31 | 26.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 20.0 | Rothschild Investment, Llc | 2024-12-31 | 8.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citigroup Inc | 2024-09-30 | 0.0 |
Artelo Fundamentals
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 915.79 K | ||||
| Shares Outstanding | 3.28 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 1.05 % | ||||
| Number Of Shares Shorted | 13.42 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 1.10 X | ||||
| EBITDA | (7.44 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | 0.87 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (3.05) X | ||||
| Target Price | 5.33 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 3.15 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 4.7 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Artelo Biosciences Piotroski F Score and Artelo Biosciences Altman Z Score analysis. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.